Research Paper Volume 11, Issue 23 pp 11010—11029

Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma

Figure 2. The relationship between recurrence score and clinical pathologic characteristics of GBM. (A) The heatmap presented PFS days, clinical pathology, and 6 representative genes of ROS for each GBM patient in ascending order of the recurrence score. PFS days, transcriptome subtype, and 6 ROS related genes showed asymmetry distribution. (B, F) The recurrence score showed no significant difference in different genders in the TCGA and CGGA databases. NSp>0.05. (C, G) Age showed no significant difference in recurrence risk groups in TCGA database. NS means p>0.05. Patients in the high risk recurrence group were older than the low risk group. **p<0.01. (D, H) The mesenchymal and neural subtypes showed significant higher recurrence scores in th TCGA and CGGA databases. NSp>0.05, **p<0.01, ***p<0.001, ****p<0.0001. (E, I) The recurrence score showed no significant difference in different MGMT promoter status GBM samples in TCGA and CGGA databases. NSp>0.05.